Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients

Caspian Journal of Internal Medicine

Volumn 2, Issue 4, 2011, Pages 309-313

  Oliaei, Farshid ^a   Hushmand, Shirin ^a   Khafri, Soraya ^a   Baradaran, Mahmoud ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nephropathy; Pentoxifylline; Proteinuria; Type II diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENTOXIFYLLINE; PLACEBO; PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84865377629     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kasper D, Brounwald E, Fauci A, et al. Harrison's principals of internal medicine. 16th ed. NewYork: MC-Grow Hill 2005; 2152-80.
2. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15.
3. Parving HH. Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41: 745-59.
4. Zhang Z, Shahrifar S, Keane WF, et al. Importance of baseline distribution of proteinuria in renal outcome trials Lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol 2005; 16: 1775-80.
5. Jensen JS, Feldt-Rasmussen B, Standgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
6. Yeo WW, Ramsay LE, Jackson PR. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 841.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
9. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702-9.
10. De Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: Titratian against urinary protein excretion. Lancet 1999; 354: 352-3.
11. Messerli FH, Mancia G, Conti R, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-93.
12. Tripathi K, Prakash J, Appaiha D, Srivastava PK. Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 1993; 64: 641-2.
13. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, et al. Pentoxifylline reduces proteinuria in insulin dependent and non-insulin dependent diabetic patients. Clin Nephrol 1995; 43: 116-21.
14. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-79.
15. Navarro JF, Mora C, Rivero A, et al. Urinary protein excretionand serum tumor necrosis factor in diabetic patients with advanced renal failure. Am J kidney Dis 1999; 33: 458-63.
16. Cooper A, Mikhail A, lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin resistant anemia in renal failure. J AM Soc Nephrol 2004; 15: 1877-82.
17. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy type II under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J AM Soc Nephrol 2005; 16: 2119-26.
18. McCormick BB, Sydor A, Akbari A, et al. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008; 52: 454-63.
19. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD a 12-month randomized trial. Am J Kidney Dis 2008; 52: 464-74.
20. Aminorroaya A, Janghorbani M, Rezvanian H, et al. Comparison of the effect of pentoxifylline and captopril in proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005; 99: 673-7.
21. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J Nephrol 2007; 20: 410-6.